Cargando…

Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model

PURPOSE: Vascular endothelial growth factor (VEGF) is the most potent angiogenic mitogen, and has been associated with angiogenesis. Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains, which can induce VEGF expression. The aims of the present study were to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xian-Jun, Yuan, Ling, Hu, Jie, Yu, Hong-Hua, Li, Tao, Lin, Shao-Fen, Tang, Shi-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388984/
https://www.ncbi.nlm.nih.gov/pubmed/22773903
_version_ 1782237263472623616
author Liang, Xian-Jun
Yuan, Ling
Hu, Jie
Yu, Hong-Hua
Li, Tao
Lin, Shao-Fen
Tang, Shi-Bo
author_facet Liang, Xian-Jun
Yuan, Ling
Hu, Jie
Yu, Hong-Hua
Li, Tao
Lin, Shao-Fen
Tang, Shi-Bo
author_sort Liang, Xian-Jun
collection PubMed
description PURPOSE: Vascular endothelial growth factor (VEGF) is the most potent angiogenic mitogen, and has been associated with angiogenesis. Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains, which can induce VEGF expression. The aims of the present study were to evaluate the heparanase expression and its relationship with VEGF in the retina of oxygen-induced retinopathy (OIR) mice, and to investigate the effect of the heparanase inhibitor phosphomannopentaose sulfate (PI-88) in the OIR retinas. METHODS: Seventy-seven newborn C57BL/6 mice were involved in this study. On postnatal day 7 (P7), pups were exposed to a hyperoxia condition (75% oxygen) for 5 days, and on P12, the mice were returned to room air. Control mice were exposed to room air from birth until P17, with normally developing retinal vasculature. PI-88 was administered intraperitoneally to OIR mice at a dose of 35.7 mg/kg/day for 5 consecutive days. The expression level of heparanase and VEGF in the retinas was assayed using immunohistochemistry, Q-RT–PCR, and western blot. RESULTS: The expression levels of heparanase and VEGF were increased in the OIR retinas compared with the control mice. The Q-RT–PCR results showed that the mRNA expression levels of heparanase and VEGF in OIR retina were increased 1.71 fold (p<0.0001) and 4.34 fold (p<0.0001), respectively. The western blot results showed that the protein expression levels of heparanase and VEGF were increased 1.49 fold (p<0.0001) and 1.72 fold (p<0.0001), respectively, in the OIR retinas compared with the normal retinas. The immunohistochemistry analysis revealed that the heparanase and VEGF signals were intense in the retinal vascular endothelia of the OIR mice but faint in those of the normal controls. The increased protein and mRNA expression levels of heparanase and VEGF in the mouse retinas were significantly decreased by PI-88 administration (p<0.0001). CONCLUSIONS: Heparanase expression was upregulated and correlated with an increase in VEGF expression in the OIR mouse retinas, and might be involved in the progress of retinopathy of prematurity. Inhibition of heparanase expression by PI-88 could be used as a novel therapeutic method for retinopathy of prematurity.
format Online
Article
Text
id pubmed-3388984
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-33889842012-07-06 Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model Liang, Xian-Jun Yuan, Ling Hu, Jie Yu, Hong-Hua Li, Tao Lin, Shao-Fen Tang, Shi-Bo Mol Vis Research Article PURPOSE: Vascular endothelial growth factor (VEGF) is the most potent angiogenic mitogen, and has been associated with angiogenesis. Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains, which can induce VEGF expression. The aims of the present study were to evaluate the heparanase expression and its relationship with VEGF in the retina of oxygen-induced retinopathy (OIR) mice, and to investigate the effect of the heparanase inhibitor phosphomannopentaose sulfate (PI-88) in the OIR retinas. METHODS: Seventy-seven newborn C57BL/6 mice were involved in this study. On postnatal day 7 (P7), pups were exposed to a hyperoxia condition (75% oxygen) for 5 days, and on P12, the mice were returned to room air. Control mice were exposed to room air from birth until P17, with normally developing retinal vasculature. PI-88 was administered intraperitoneally to OIR mice at a dose of 35.7 mg/kg/day for 5 consecutive days. The expression level of heparanase and VEGF in the retinas was assayed using immunohistochemistry, Q-RT–PCR, and western blot. RESULTS: The expression levels of heparanase and VEGF were increased in the OIR retinas compared with the control mice. The Q-RT–PCR results showed that the mRNA expression levels of heparanase and VEGF in OIR retina were increased 1.71 fold (p<0.0001) and 4.34 fold (p<0.0001), respectively. The western blot results showed that the protein expression levels of heparanase and VEGF were increased 1.49 fold (p<0.0001) and 1.72 fold (p<0.0001), respectively, in the OIR retinas compared with the normal retinas. The immunohistochemistry analysis revealed that the heparanase and VEGF signals were intense in the retinal vascular endothelia of the OIR mice but faint in those of the normal controls. The increased protein and mRNA expression levels of heparanase and VEGF in the mouse retinas were significantly decreased by PI-88 administration (p<0.0001). CONCLUSIONS: Heparanase expression was upregulated and correlated with an increase in VEGF expression in the OIR mouse retinas, and might be involved in the progress of retinopathy of prematurity. Inhibition of heparanase expression by PI-88 could be used as a novel therapeutic method for retinopathy of prematurity. Molecular Vision 2012-06-20 /pmc/articles/PMC3388984/ /pubmed/22773903 Text en Copyright © 2012 Molecular Vision. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liang, Xian-Jun
Yuan, Ling
Hu, Jie
Yu, Hong-Hua
Li, Tao
Lin, Shao-Fen
Tang, Shi-Bo
Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model
title Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model
title_full Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model
title_fullStr Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model
title_full_unstemmed Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model
title_short Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model
title_sort phosphomannopentaose sulfate (pi-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388984/
https://www.ncbi.nlm.nih.gov/pubmed/22773903
work_keys_str_mv AT liangxianjun phosphomannopentaosesulfatepi88suppressesangiogenesisbydownregulatingheparanaseandvascularendothelialgrowthfactorinanoxygeninducedretinalneovascularizationanimalmodel
AT yuanling phosphomannopentaosesulfatepi88suppressesangiogenesisbydownregulatingheparanaseandvascularendothelialgrowthfactorinanoxygeninducedretinalneovascularizationanimalmodel
AT hujie phosphomannopentaosesulfatepi88suppressesangiogenesisbydownregulatingheparanaseandvascularendothelialgrowthfactorinanoxygeninducedretinalneovascularizationanimalmodel
AT yuhonghua phosphomannopentaosesulfatepi88suppressesangiogenesisbydownregulatingheparanaseandvascularendothelialgrowthfactorinanoxygeninducedretinalneovascularizationanimalmodel
AT litao phosphomannopentaosesulfatepi88suppressesangiogenesisbydownregulatingheparanaseandvascularendothelialgrowthfactorinanoxygeninducedretinalneovascularizationanimalmodel
AT linshaofen phosphomannopentaosesulfatepi88suppressesangiogenesisbydownregulatingheparanaseandvascularendothelialgrowthfactorinanoxygeninducedretinalneovascularizationanimalmodel
AT tangshibo phosphomannopentaosesulfatepi88suppressesangiogenesisbydownregulatingheparanaseandvascularendothelialgrowthfactorinanoxygeninducedretinalneovascularizationanimalmodel